Pharsight

Drugs that contain Budesonide

1. Entocort Ec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5643602 PADAGIS US Oral composition for the treatment of inflammatory bowel disease
Jul, 2014

(9 years ago)

US5643602

(Pediatric)

PADAGIS US Oral composition for the treatment of inflammatory bowel disease
Jan, 2015

(9 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Patient Population(NPP) Apr 29, 2019
M(M-178) Apr 29, 2019

Market Authorisation Date: 02 October, 2001

Treatment: Treatment of mild to moderate active chrohn's disease involving the ileum and/or the ascending colon and the maintenance of clinical remission of mild to moderate crohn's disease involving the ileum a...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

How can I launch a generic of ENTOCORT EC before it's drug patent expiration?
More Information on Dosage

ENTOCORT EC family patents

Family Patents

2. Eohilia patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8975243 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US8679545 TAKEDA PHARMS USA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US9119863 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US8497258 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US11197822 TAKEDA PHARMS USA Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US11413296 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Nov, 2026

(2 years from now)

US11357859 TAKEDA PHARMS USA Compositions for the treatment of gastrointestinal inflammation
Nov, 2028

(4 years from now)

US10293052 TAKEDA PHARMS USA Compositions for the treatment of gastrointestinal inflammation
Nov, 2028

(4 years from now)

US9050368 TAKEDA PHARMS USA Corticosteroid compositions
Aug, 2029

(5 years from now)

US8324192 TAKEDA PHARMS USA Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
Aug, 2029

(5 years from now)

US11564934 TAKEDA PHARMS USA Stable corticosteroid compositions
Jan, 2039

(14 years from now)

US11260064 TAKEDA PHARMS USA Stable corticosteroid compositions
Jan, 2039

(14 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-466) Feb 09, 2031
New Product(NP) Feb 09, 2027

Market Authorisation Date: 09 February, 2024

Treatment: Treatment of eosinophilic esophagitis

Dosage: SUSPENSION;ORAL

More Information on Dosage

EOHILIA family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Ortikos patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9707182 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(12 years from now)

US10172802 SUN PHARM INDS INC Oral pharmaceutical dosage forms of budesonide
Sep, 2036

(12 years from now)

Market Authorisation Date: 13 June, 2019

Treatment: Treatment of mild to moderate active crohn's disease involving the ileum and/or the ascending colon

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

ORTIKOS family patents

Family Patents

4. Pulmicort Flexhaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6027714 ASTRAZENECA Formulation for inhalation
Jan, 2018

(6 years ago)

US6287540 ASTRAZENECA Formulation for inhalation
Jan, 2018

(6 years ago)

US7143764 ASTRAZENECA Inhalation device
Mar, 2018

(6 years ago)

US6142145 ASTRAZENECA Inhalation device
May, 2018

(6 years ago)

Market Authorisation Date: 12 July, 2006

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PULMICORT FLEXHALER family patents

Family Patents

5. Pulmicort Respules patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7524834 ASTRAZENECA Sterile powders, formulations, and methods for producing the same
Nov, 2018

(5 years ago)

US6598603 ASTRAZENECA Method for treating respiratory diseases
Dec, 2018

(5 years ago)

US6899099 ASTRAZENECA Method for treating a respiratory disease
Dec, 2018

(5 years ago)

US7524834

(Pediatric)

ASTRAZENECA Sterile powders, formulations, and methods for producing the same
May, 2019

(5 years ago)

US6899099

(Pediatric)

ASTRAZENECA Method for treating a respiratory disease
Jun, 2019

(4 years ago)

US6598603

(Pediatric)

ASTRAZENECA Method for treating respiratory diseases
Jun, 2019

(4 years ago)

Market Authorisation Date: 08 August, 2000

Treatment: Treatment of asthma (maintenance and prophylactic therapy); Once daily treatment of asthma with nebulized budesonide

Dosage: SUSPENSION;INHALATION

How can I launch a generic of PULMICORT RESPULES before it's drug patent expiration?
More Information on Dosage

PULMICORT RESPULES family patents

Family Patents

6. Rhinocort patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6686346 ASTRAZENECA Formulation
Apr, 2017

(7 years ago)

US6986904 ASTRAZENECA Formulation
Apr, 2017

(7 years ago)

US6291445 ASTRAZENECA Low dose budesonide formulations and uses thereof
Apr, 2017

(7 years ago)

US6291445

(Pediatric)

ASTRAZENECA Low dose budesonide formulations and uses thereof
Oct, 2017

(6 years ago)

US6986904

(Pediatric)

ASTRAZENECA Formulation
Oct, 2017

(6 years ago)

US6686346

(Pediatric)

ASTRAZENECA Formulation
Oct, 2017

(6 years ago)

Market Authorisation Date: 23 March, 2015

Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of RHINOCORT before it's drug patent expiration?
More Information on Dosage

RHINOCORT family patents

Family Patents

7. Tarpeyo patents expiration

TARPEYO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8491932 CALLIDITAS Compositions for the oral delivery of corticosteroids
May, 2029

(4 years from now)

US11896719 CALLIDITAS Pharmaceutical compositions
Jan, 2043

(18 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-389) Dec 15, 2028
Orphan Drug Exclusivity(ODE-464) Dec 20, 2030
New Product(NP) Dec 15, 2024

Market Authorisation Date: 15 December, 2021

Treatment: Reduction in loss of kidney function in adults with primary immunoglobulin a nephropathy (igan) who are at risk of disease progression; Reduction in loss of kidney function and reduction of proteinuri...

Dosage: CAPSULE, DELAYED RELEASE;ORAL

More Information on Dosage

TARPEYO family patents

Family Patents

8. Uceris patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5914122 SALIX Stable budesonide solutions, method of preparing them and use of these solutions as enema preparations and pharmaceutical foams
Dec, 2015

(8 years ago)

US10143698 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

US10105374 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

US8784888 SALIX Controlled release and taste masking oral pharmaceutical composition
Jun, 2020

(3 years ago)

US8293273 SALIX Controlled release and taste masking oral pharmaceutical composition
Jun, 2020

(3 years ago)

US7431943 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

USRE43799 SALIX Controlled release and taste masking oral pharmaceutical composition
Jun, 2020

(3 years ago)

US9532954 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

US7410651 SALIX Controlled release and taste masking oral pharmaceutical composition
Jun, 2020

(3 years ago)

US10064878 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

US9320716 SALIX Controlled release and taste masking oral pharmaceutical compositions
Jun, 2020

(3 years ago)

US9192581 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US8895064 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US10660858 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US10307375 SALIX Controlled release and taste masking oral pharmaceutical composition
Sep, 2031

(7 years from now)

US9132093 SALIX Controlled release and taste making oral pharmaceutical composition
Sep, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Oct 07, 2017

Market Authorisation Date: 07 October, 2014

Treatment: Induction of remission in patients with active, mild to moderate ulcerative colitis

Dosage: AEROSOL, FOAM;RECTAL; TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of UCERIS before it's drug patent expiration?
More Information on Dosage

UCERIS family patents

Family Patents